Thursday 25 February 2016

The Oprah Effect can it short squeeze again

There are 2 sides to a trade LONG, the buy and the sell is one side or SHORT sell and then the buy. As a short sell bias trader I focus on potential dirty dark side of the trade opportunities.The one thing you fear shorting is the squeeze as you have to buy shares to exit your position you can be squeezed to buy higher and higher as is the case currently underway with $WTW Weight Watchers.

$WTW at last report has 17 767 000 shares or 64.42% of the floating (available shares) short. This is an epic recipe with up coming earnings reported end of today as a catalyst for the one thing that puts fear into us short sellers....A squeeze. After hours trading last night saw a 500 000 transaction go through at 4:04 for $15.36. That was one trade for $7 680 000. Why other than the size of the trade is this important? If you look at the chart you will see $15.36 is the bottom of the sell off from $20.



Using the mentality that former support becomes resistance and former resistance support you have a small pocket in the $17 range but skies are clear till $20. This could be a 30% return on your investment as based on the amount of shares trading average it will take 6.2 days to cover. We have hours until the earnings come out and we will see the true power of the Oprah Effect.

Weight Watchers is a well-known weight-management service which gained a lot of attention when Oprah Winfrey acquired a sizable stake in the company. In addition last December, Oprah announced a 10% stake and a board of directors seat.

But let's paint the time line first of the last 6 months of ownership filings
2015-10-21 Artal International S.C.A files 46.3% ownership at 29 443 300 shares
2015-10-28 Oprah declares with options 14.72% ownership 9 875 571 shares
2015-11-06 Cohen & EverPoint Asset Management 5.7% ownership 3 649 700 shares
2016-02-12 FMR/Johnson & Fidelity Low-Priced Stock Fund 32.6% ownership 20 744 100 shares
2016-02-12 First Manhattan Co. 1.23% ownership 78 479
2016-02-16 Capital Research Global Investors 0% Possible short position move
2016-02-16 Point72 Asset Management 3.9% ownership 2 482 595 shares

While these numbers pulled from the SEC filings reported http://www.sec.gov/index.htm may also include yet to be redeemed options.

With everything here put together in my opinion $WTW is a catalyst for a SQUEEZE not a short price action will determine.

Monday 15 February 2016

Could Intercept Pharmaceutical be the Pump and Dump of the month or even the year


Intercept Pharmaceutical on the Pump and Dump watch

From pure technicals the stock did break out but it hit resistance heavily at $128.75 and has been down trending ever since 12:50 with the lowest price coming $92.45 3 mins after close on 18,570 shares 28.19% drop. Some dumped read on to find out why.

If you look back last month I gave a similar warning on Synaptics $SYNA you can see how that played out, Intercept Pharmaceutical $ICPT is now playing that same game.

With the earnings miss of $0.46 a share it proves that the company is not profitable even though they have $558.7 million in cash. Due to 2 reasons that money came from TWO (2) public follow ons in 2015 and they estimate a need of $400 million just for the current trials alone. Any new trials will require more funding with such a small float the dilution could be as much as 20% in share float.

Intercept posts SEC 13G listed 6.4% ownership = 1,567,537 on FEB10th NO PRICE listed for avg share means this is worthless information but you can bet the acquisition was completed in the price $91.44-$96.01 or much lower.  http://www.sec.gov/Archives/edgar/data/1270073/000142284916000618/edgicpt.txt

Less than 10% can sell at their hearts content into any pop which makes this an easy game, file 13G with no share per price avg, bump price, halt it saying looking for buyer, sell into pop, dump after hours if needed. Technical traders would have bought the break out and would not see the after hours drop on any intraday scans.

Based on this intercept is a better short than long because the fundamentals have not changed this still is not going to make any money till the FDA approves and that is not a sure thing.

Results weren`t great in trial but they were positive in using obeticholic acid as a treatment for primary biliary cirrhosis, or PBC, an autoimmune disease that causes bile acids to build up and destroy the liver.

Originally, obeticholic acid, also known as OCA, was slated to be approved (or given a complete response letter detailing what would need to be corrected for approval) in February. However, additional data requests from the Food and Drug Administration wound up pushing the PDUFA date back three months, to May 29, 2016. The FDA also set up a panel review for April 7, 2016.

If this was a sure thing then why do we have selling from insiders and the dump at 4:03 of 18,570 shares with a final price of $92.45.


Insiders selling none are buying since 2014

Insider Trading: Sales

Insider
Price
Amount
Relationship
Remaining Holdings
Date
Form 4
$103.56
128
Officer
7,621
2016-02-01
$129.99
104
Officer
11,700
2016-01-13
$124.78
624
Officer
11,804
2016-01-12
$145.90
469
Officer
7,749
2016-01-04
$145.90
428
Officer
24,892
2016-01-04
$145.90
40
Officer
25,320
2016-01-04
$145.90
496
Officer
40,911
2016-01-04
$145.90
37
Officer
41,407
2016-01-04
$145.90
125
Officer, Director
529,556
2016-01-04
$145.90
2,001
Officer, Director
529,681
2016-01-04
$157.45
1,000
Officer
28,395
2015-12-15
$157.38
2,500
Officer
29,395
2015-12-15
$182.96
1,150
Officer
12,428
2015-11-25
$167.00
973
Director
962
2015-11-20
$179.49
1,500
Officer
28,395
2015-11-16
$178.00
2,764
Officer
29,895
2015-11-16
$198.25
1,000
Director
2,166
2015-11-10
$204.15
3,500
Officer
29,159
2015-11-10
$160.24
125
Officer
8,218
2015-11-02
$182.22
974
Director
962
2015-10-20

Insider Trading: Purchases

Insider
Price
Amount
Relationship
Remaning Holdings
Date
Form 4
$139.86
800
Director
1,292
2014-12-15
$163.27
500
Director
7,642
2014-11-12
$173.67
1,000
Director
7,142
2014-11-12
$158.18
500
Director
6,142
2014-11-12
$15.00
333,334
Large Shareholder
2,150,634
2012-10-16
$15.00
700,000
Director
700,000
2012-10-16
$15.00
333,334
Large Shareholder, Director
2,150,634
2012-10-16

Lastly if someone did want to buy this company why would they pay a premium, buy before the FDA approval and why would the company be looking now to sell so close to the "approval"? Smells fishy $SYNA fishy to me

Based on this I am calling this a SHORT not a squeeze.